Subcutaneous · Amylin analog
NNC0638-0355
1 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
1
Active
1
Recruiting
0
Completed
0
Sites
1
Countries
1
Endpoints
6
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
1
Trials by status
Active, not recruiting
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
6
Most-measured metrics
Top 20 metrics across this asset's endpoints
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT06577766A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity | NNC0638-0355 Obesity / overweight | BMI 25-34.9 | Ph 1 | Active, not recruiting | 1 | Sep 2026 | — |